Metabolic Research Peptides Canada
Six metabolic research compounds, each with its receptor target and its published research. GLP-3/RT is $69.99 for 10 mg, and everything ships tracked from Vancouver.
- Free shipping on orders over $300
- 10% off your first order with code WELCOME10
- ~10% off when you pay by Interac e-Transfer
- Tracked Xpresspost from Vancouver
Metabolic research peptides
This collection groups the compounds studied in metabolic and weight-management research, from incretin-receptor agonists to an amylin analogue, an enzyme inhibitor and a growth-hormone fragment. Each is described by its receptor target and what its trials measured, for research use only.
Compounds by receptor target
| Compound | Target | Research stage | What was measured | Source | Price (CAD) |
|---|---|---|---|---|---|
| GLP-3/RT (retatrutide) | GIP, GLP-1 and glucagon receptors | Phase 2 trial | Change in body weight over 48 weeks | NEJM 2023 | $69.99 |
| GLP-2/Tirz (tirzepatide) | GIP and GLP-1 receptors | Phase 3 trials | Body weight; head-to-head vs semaglutide | NEJM 2022, 2025 | $54.99 |
| Cagrilintide | Amylin receptors | Phase 2; phase 3 with semaglutide | Body weight | Lancet 2021; NEJM 2025 | $74.99 |
| 5-Amino-1MQ | NNMT enzyme (small molecule) | Mouse background study | NNMT levels and diet response | Nature 2014 | $79.99 |
| AOD-9604 | Growth-hormone fragment (176–191) | Mouse study; human safety study | Lipid metabolism; tolerability | Endocrinology 2001; JEM 2013 | $79.99 |
GLP-3/RT (retatrutide)
GLP-3/RT is the research name for retatrutide, a triple agonist at the GIP, GLP-1 and glucagon receptors. A 48-week phase 2 trial in adults with obesity measured change in body weight. More in the GLP-3/RT research post and, for the limits, what retatrutide can’t promise.

GLP-3/RT 10 mg vial
$69.99 CAD · 10mg
- What people use it for:
- The most-searched product on the site.
- What the research looks at:
- A triple agonist (GIP, GLP-1 and glucagon receptors); a 48-week phase 2 trial in adults with obesity measured change in body weight.
- Source:
- NEJM 2023
GLP-2/Tirz (tirzepatide)
GLP-2/Tirz is tirzepatide, a dual agonist at the GIP and GLP-1 receptors with a large body of phase 3 trial data, including a 2025 head-to-head trial with semaglutide as the comparator. Compare it on GLP-2/Tirz vs GLP-3/RT, and see what tirzepatide can’t promise.

GLP-2/Tirz 10 mg vial
$54.99 CAD · 10mg
- What people use it for:
- Dual-agonist research.
- What the research looks at:
- A dual GIP and GLP-1 receptor agonist studied in large phase 3 trials, including a 2025 head-to-head trial against semaglutide.
Cagrilintide
Cagrilintide is a long-acting amylin analogue. It was studied in a 2021 phase 2 trial and, combined with semaglutide, in 2025 phase 3 trials. The cagrilintide trial data post and what cagrilintide can’t promise go further; see also cagrilintide vs GLP-3/RT.

Cagrilintide 10 mg vial
$74.99 CAD · 10mg
- What people use it for:
- Amylin-pathway research.
- What the research looks at:
- A long-acting amylin analogue studied in a phase 2 trial (2021) and, combined with semaglutide, in 2025 phase 3 trials.
- Sources:
- Lancet 2021; NEJM 2025
5-Amino-1MQ
5-Amino-1MQ is a small molecule, not a peptide, that blocks the enzyme NNMT. Interest in it comes largely from a 2014 mouse study in which lowering NNMT levels changed how the animals responded to a high-fat diet; that study did not test 5-Amino-1MQ itself. More in the 5-Amino-1MQ research post.

5-Amino-1MQ 50 mg vial
$79.99 CAD · 50mg
- What people use it for:
- NNMT-pathway research.
- What the research looks at:
- A small-molecule NNMT inhibitor, not a peptide. The key background study (2014) reduced NNMT levels in mice; it did not test this compound.
- Source:
- Nature 2014

5-Amino-1MQ nasal spray
$84.99 CAD · 10ml Nasal Spray
- What people use it for:
- 5-Amino-1MQ ready-mixed.
- What the research looks at:
- The same compound; the spray format has not been studied.
AOD-9604
AOD-9604 is a fragment of human growth hormone (amino acids 176–191). It was studied for lipid metabolism in obese mice in 2001 and in a human safety and tolerability study in 2013.

AOD-9604 10 mg vial
$79.99 CAD · 10mg
- What people use it for:
- Growth-hormone fragment research.
- What the research looks at:
- A fragment of human growth hormone (176–191) studied for lipid metabolism in obese mice (2001) and in a human safety and tolerability study (2013).
- Sources:
- Endocrinology 2001; J Endocrinol Metab 2013
Reading the trial data
The trials above enrolled specific groups of adults under clinical supervision, and their results describe those groups, not what a compound will do for anyone else. The posts linked in each section explain how each trial was designed and what it measured. For mitochondrial research, see the Longevity collection.
Delivery and quality
Orders are processed in 1–2 business days and ship tracked by Canada Post Xpresspost from Vancouver: British Columbia in 1–2 business days; Alberta, Saskatchewan and Manitoba in 2–3; Ontario and Québec in 2–3 in major cities and 3–4 rural; Atlantic Canada in 2–4; territories and remote addresses in 3–7. The shipping page has the full table.
Every lot is tested by an independent lab for purity and content by HPLC; lab results explains how.
Shop the Metabolic research collection
6 products · prices in CAD

GLP-3/RT

GLP-2/Tirz

Cagrilintide

5-Amino-1MQ

5-Amino-1MQ 10ml Nasal Spray

AOD-9604
Questions about a compound for your research? Message Kobi on WhatsApp
FAQ
What is GLP-3/RT?
GLP-3/RT is the research name for retatrutide, a peptide that acts on three receptors: GIP, GLP-1 and glucagon. It has been studied in clinical trials; a 48-week phase 2 trial published in 2023 measured change in body weight in adults with obesity. Popular Peptides sells it as a 10 mg research vial.
What is the difference between GLP-2/Tirz and GLP-3/RT?
GLP-2/Tirz (tirzepatide) acts on two receptors, GIP and GLP-1. GLP-3/RT (retatrutide) adds a third, the glucagon receptor. Tirzepatide has a large body of phase 3 trial data; retatrutide is the newer of the two.
What is 5-Amino-1MQ?
5-Amino-1MQ is a small molecule, not a peptide, that blocks the enzyme NNMT. Interest in it comes largely from a 2014 mouse study in which lowering NNMT levels changed how the animals responded to a high-fat diet; that study did not test 5-Amino-1MQ itself. Popular Peptides sells it as a 50 mg vial and a ready-mixed nasal spray.
Read more
- GLP-3/RT research
- Cagrilintide trial data
- 5-Amino-1MQ research
- GLP-2/Tirz vs GLP-3/RT
- Cagrilintide vs GLP-3/RT
- Shipping times by province
Other collections: Longevity · Muscle & performance
Where to start: GLP-3/RT
Carries the site’s Best Seller badge and is the most-searched product on the site.
All items are sold strictly for in vitro laboratory research use only: they are not for human or veterinary consumption.